The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.

Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.34 per share a year ago.

Gilead Sciences has dropped 15% YTD, impacted by disappointing trial results from Trodelvy after acquiring Immunomedics for over $20 billion. Despite challenges, the company had a financially stron...

Pfizer is busy growing income streams to replace its big COVID-related revenue from years past. Paycom is profitably helping companies help themselves with self-service software.

Gilead Sciences (GILD) reachead $72.41 at the closing of the latest trading day, reflecting a -0.21% change compared to its last close.

When I think of biotech stocks, I imagine volatile share prices and plenty of red ink. I also think of big-time shareholder returns for the industry's winners.

Dividend stocks can deliver both reliable income and substantial capital appreciation over long periods of time. Investing $51,000 across these three dividend-paying options could yield about $3,00...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $71.64, denoting a +1.17% change from the preceding trading day.

The latest trading day saw Gilead Sciences (GILD) settling at $68.75, representing a +1.46% change from its previous close.

While Gilead (GILD) has been reeling under pressure year to date due to pipeline setbacks, holding on to this biotech giant will be prudent at current levels.

Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revol...

Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in it...

Gilead (GILD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r...

Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.